Selective delivery molecules and methods of use

1. A selective delivery molecule of Formula I:

[D A - c A ]-A-[ c M -M]X-B-[ c B -D B ];  Formula I

wherein,

X is a peptide linker cleavable by a protease;

A is a peptide with a sequence comprising a series of 5 glutamates;

B is a peptide with a sequence comprising a series of 8 arginines;

c A , c B , and c m each independently comprise 0-1 naturally-occurring amino acid or

non-naturally-occurring amino acid;

M is a polyethylene glycol (PEG) polymer having an average molecular weight of 500 Da to 10 kDa; and

D A and D B are independently selected from a therapeutic agent and an imaging agent, wherein at least one of D A and D B is a therapeutic agent; and

wherein [c M -M] is bound to at any position on A or X, [D A -c A ] is bound to any amino acid on A, and [c B -D B ] is bound to any amino acid on B.

2. The molecule of claim 1 , wherein c A , c B , and c M are each independently selected from D-cysteine, D-glutamate, lysine, and para-4-acetyl L-phenylalanine.

3. The molecule of claim 2 , wherein c B is D-cysteine.

4. The molecule of claim 2 , wherein c A is D-glutamate or lysine.

5. The molecule of claim 2 , wherein c m is para-4-acetyl L-phenylalanine.

6. The molecule of claim 1 , wherein X is cleavable by a matrix metalloproteinase.

7. The molecule of claim 6 , wherein X comprises an amino acid sequence that is cleavable by MMP2, MMP7, MMP9, or MMP14.

8. The molecule of claim 1 , wherein X comprises an amino acid sequence selected from: PLGLAG (SEQ ID NO: 2), PLG-C(me)-AG (SEQ ID NO: 1), RPLALWRS (SEQ ID NO: 7), ESPAYYTA (SEQ ID NO: 8), DPRSFL (SEQ ID NO:9), PPRSFL (SEQ ID NO: 10), RLQLKL (SEQ ID NO: 11), and RLQLK(Ac) (SEQ ID NO: 12).

9. The molecule of claim 1 , wherein M is a PEG polymer having an average molecular weight selected from: 500 Da, 2 kDa, 5 kDa, and 10 kDa.

10. The molecule of claim 1 , wherein the therapeutic agent comprises a chemotherapeutic agent, a steroid, an immunotherapeutic agent, a targeted therapy agent, an anti-inflammatory agent, an anti-cancer agent, or a combination thereof.

11. The molecule of claim 1 , wherein the therapeutic agent comprises B cell receptor pathway inhibitor, a CD79A inhibitor, a CD79B inhibitor, a CD19 inhibitor, a Lyn inhibitor, a Syk inhibitor, a PI3K inhibitor, a Blnk inhibitor, a PLCγ inhibitor, a PKCβ inhibitor, an antibody, an IAP inhibitor, an mTOR inhibitor, a radioimmunotherapeutic, a DNA damaging agent, a proteosome inhibitor, a histone deacytlase inhibitor, a protein kinase inhibitor, a hedgehog inhibitor, an Hsp90 inhibitor, a telomerase inhibitor, a Jak1/2 inhibitor, a protease inhibitor, a PKC inhibitor, a PARP inhibitor, an anti-TNF agent, an IL-1 receptor antagonist, an IL-2 receptor antagonist, a cytotoxic agent, an immunomodulatory agent, an antibiotic, a T-cell co-stimulatory blocker, a B cell depleting agent, an immunosuppressive agent, an alkylating agent, an anti-metabolite, a plant alkaloid, a terpenoids, a topoisomerase inhibitor, an antitumor antibiotic, a hormonal therapy, an anti-diabetes agent, a leukotriene inhibitor, or combinations thereof.

12. A method of delivering a therapeutic agent to a tissue of interest in an individual in need thereof, comprising contacting the tissue of interest with a selective delivery molecule as claimed in claim 1 .

13. The method of claim 12 , wherein the tissue of interest is cancerous tissue.

14. The method of claim 12 , wherein the tissue of interest is: breast cancer tissue, colorectal cancer tissue, squamous cell carcinoma tissue, skin cancer tissue, prostate cancer tissue, melanoma tissue, thyroid cancer tissue, ovarian cancer tissue, cancerous lymph node tissue, cervical cancer tissue, lung cancer tissue, pancreatic cancer tissue, head and neck cancer tissue, esophageal cancer tissue, or sarcoma.

15. The method of claim 12 , wherein the tissue of interest is breast or colon cancer tissue.

16. The method of claim 12 , wherein the molecule is administered intravenously.

17. A pharmaceutical composition comprising a selective delivery molecule as claimed in claim 1 , and a pharmaceutically-acceptable excipient.

18. The molecule of claim 1 , wherein D A and D B are selected from the same therapeutic agent.

19. The molecule of claim 1 , wherein D A and D B are selected from different therapeutic agents.

20. The molecule of claim 1 , wherein D B is a therapeutic agent.